Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Contact
201 East Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,726.20 | 60.58 | 0.79% |
| DAX 40 | 22,653.86 | 273.67 | 1.22% |
| Dow JONES (US) | 46,208.47 | 631.00 | 1.38% |
| FTSE 100 | 9,894.15 | 24.18 | -0.24% |
| HKSE | 24,840.62 | 458.15 | 1.88% |
| NASDAQ | 21,946.76 | 299.15 | 1.38% |
| Nikkei 225 | 52,134.91 | 619.42 | 1.20% |
| NZX 50 Index | 12,701.75 | 197.97 | -1.53% |
| S&P 500 | 6,581.00 | 74.52 | 1.15% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,849.76 | 36.48 | 0.96% |